This article has been updated from a previous version to retract information originally provided by Abbott in a statement.

NEW YORK (GenomeWeb) – Abbott today announced that it has signed an exclusive licensing agreement with the Institut Curie for a biomarker for bladder cancer.

Genetic mutations in FGFR3 can be used for early detection, disease monitoring, and predicting patient outcomes in both urine and tissue-based testing. FGFR3 gene mutations are seen in about 70 percent of low-grade and 15 to 20 percent of high-grade bladder cancer cases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.